Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 plus chemotherapy in SMARCA4-deficient NSCLC
NCT07200947Phase 2Not yet recruiting
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of iparomlimab + tuvonralimab in non-small cell lung cancer (NSCLC). Planned start Dec 2025; status: not yet recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07200947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07200947.